Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113113 · ClinicalTrials.gov registry record · Phase 1
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00113113 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT00113113, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.
Interventions
- DRUG Rubitecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113113
The ClinicalTrials.gov registry entry for NCT00113113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rubitecan is the first listed.
NCT00113113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113113 about?
NCT00113113 is a clinical study titled "Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction". Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.
What is the current status of trial NCT00113113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2001-08.
What interventions are being tested in trial NCT00113113?
The interventions under investigation include: Rubitecan (DRUG).
Who is sponsoring clinical trial NCT00113113?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.